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Carbapenem-resistant Acinetobacter spp. mainly Acinetobacter baumannii are
frequently causing nosocomial infections with high mortality. In this study, the efficacy
of the Eazyplex R© SuperBug Complete A system, based on loop-mediated isothermal
amplification (LAMP), to detect the presence of carbapenemases in Acinetobacter
spp. directly from bronchoalveolar lavage (BAL) samples was assessed. A total
of 22 Acinetobacter spp. strains producing OXA-23, OXA-40, OXA-58, NDM, and
IMP were selected. Eazyplex SuperBug Complete A kit, used with the Genie
II device, is a molecular diagnostics kit that detects a selection of genes that
express carbapenemases (blaKPC, blaNDM, blaVIM, blaOXA−48, blaOXA−23, blaOXA−40, and
blaOXA−58). Negative BAL samples were identified, McFarland solutions were prepared
from each of the 22 Acinetobacter strains and serial dilutions in saline solution were
made to finally spike BAL samples to a concentration of 102 and 103 CFU/ml. Fifteen
concentrations out of the 44 tested out did not provide detection of the carbapenemase-
producing gene, all but one being at the lowest concentration tested at 102 CFU/ml;
therefore, the limit of sensitivity is 103 CFU/ml. This assay represents the kind of
advantages that investing in molecular diagnostics brings to the clinical practice,
allowing the identification of carbapenemases in less than 30 min with a sensitivity of
103 CFU/ml.
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INTRODUCTION
Carbapenems are potent β-lactam antibiotics with broad-
spectrum and bactericidal mode of action (Codjoe and Donkor,
2017). Their use was increased due to the spread of extended
spectrum β-lactamase-producing Enterobacteriales toward whom
they are active (Hawkey and Livermore, 2012; Bush and Bradford,
2020). Carbapenems are considered one of the most efficacious
antimicrobials to treat bacterial infections (Codjoe and Donkor,
2017). However, resistance by carbapenemases did not take
long to appear, and it poses a major threat to public health
(Hawkey and Livermore, 2012).
Acinetobacter spp. members and specially carbapenem-
resistant Acinetobacter baumannii (CRAB) are among the world’s
most dangerous pathogen threats. CRAB has been classified as
a critical priority pathogen by the WHO’s priority pathogens
to guide research and development (R&D) of new antibiotics
(Tacconelli et al., 2018; World Health Organization, 2019) and
as an urgent threat that requires aggressive action by Centers
for Disease Control and Prevention (CDC) (Centers for Disease
Control, 2019).
Even though community-acquired Acinetobacter infections
can occur, the most common and acute infections happen in
the nosocomial setting. Acinetobacter lurks around intensive
care units and surgical wards causing a number of infections
(e.g., on burns and soft tissue, urinary tract, and bloodstream)
and specially ventilator-associated pneumonia (VAP) in patients
under mechanical ventilation (Evans et al., 2012; Bush and
Bradford, 2020).
Ventilator-associated pneumonia develops in intensive care
units in patients under ventilation for at least 48 h. Rapid
diagnostic of VAP-causing pathogens is of utmost importance:
VAP patients not only have longer hospital stays and need
more antibiotics, therefore their treatment is more expensive,
but also have higher mortality (Torres et al., 2017; Bonell et al.,
2019).
This study aims to evaluate Eazyplex R© SuperBug Complete
A based on loop-mediated isothermal amplification (LAMP)
for detecting carbapenemase produced by Acinetobacter directly
from inoculated bronchoalveolar lavage (BAL) samples.
MATERIALS AND METHODS
Eazyplex R© SuperBug Complete A kit (AmplexDiagnostics
GmbH, Germany), used with the Genie II device (OptiGene,
Horsham, United Kingdom), is a molecular diagnostics kit
that detects a selection of genes that express carbapenemases
(including metallo-β-lactamases and oxacillinases). Results after
detection of bacterial DNA are presented within 30 min.
The kit is composed of eight tube strips each with a mix of
lyophilized agents for the amplification of one of the following
seven genes: blaKPC, blaNDM , blaVIM , blaOXA−48, blaOXA−23,
blaOXA−40, and blaOXA−58. The eighth tube is an internal
inhibitory control.
Once the samples are prepared and the strip is inside the Genie
II device, a LAMP is performed. The reaction is incubated at
66◦C for 30 min, and detection is performed via fluorescence
excitation, for up to two strips at a time.
A total of 22 Acinetobacter spp. strains producing OXA-23,
OXA-40, OXA-58, NDM, and IMP were selected (Table 1).
Isolate identification was performed via MALDI-TOF/MS
(Bruker Daltonics, Bremen, Germany). Carbapenemase
gene detection was checked via conventional PCR for
each of the strains (Woodford et al., 2006; Kulah et al.,
2010; Solé et al., 2011). The strains selected basically were
epidemiologically unrelated due to its different sequence types
(ST) or geographical origins.
Negative BAL samples were identified and collected at
the Clinical Microbiology Laboratory from Hospital Clinic of
Barcelona; samples were stored at −80◦C. McFarland solutions
were prepared from each of the 22 Acinetobacter strains, and
serial dilutions in saline solution were made to finally spike BAL
samples to a concentration of 102 and 103 CFU/ml.
The protocol consisted in: centrifugation of 850 µl of the 102
and 103 spiked BAL samples (at 14,000 g for 5 min), addition of
500 µl of resuspension and lysis fluid (RALF, provided with the
kit) to the pellet obtained, incubation at 99◦C for 2 min and a
final centrifugation step (4,000 rpm for 2 min). Finally, 25 µl of
the supernatant was added to each tube of the assay strip. The
hands-on time took a maximum of 15 min per strain.
RESULTS AND DISCUSSION
Increasing resistance to antimicrobials and specifically
carbapenems is reported in A. baumannii in the past
years. In Spain, there has been an increase of up to 40%
in A. baumannii clinical isolates presenting resistance to
carbapenems from 2000 to 2010; 86% of the 446 A. baumannii
clinical isolates presented resistance to carbapenems in 2010’s
study (Fernández-Cuenca et al., 2013).
This situation is rather common. Recently, European Centre
for Disease Prevention and Control (ECDC) has reported
≥50% of Acinetobacter spp. invasive isolates present resistance
to carbapenems in Hungary, Poland, Bulgaria, Latvia, Italy,
Spain, Cyprus, Romania, Lithuania, Greece, and Croatia in
2018’s Annual Report of the European Antimicrobial Resistance
Surveillance Network (European Centre for Disease Prevention
and Control, 2018).
Current effective antibiotics for the treatment of CRAB are
scarce and are not the most suitable therapeutic agents due to
poor pharmacokinetics, toxicity (as in the case of polymyxins),
and emergence of resistance (Garnacho-Montero et al., 2015).
Chromosome and/or plasmid encoded carbapenemases are the
main mechanism of resistance to carbapenems in CRAB (Roca
et al., 2012; Bush and Bradford, 2020); thus, rapid detection
of carbapenemases is key to guide effective antibiotic therapies
(Garnacho-Montero et al., 2015).
Although the Complete A kit is not specific for Acinetobacter,
carbapenemase coverage is enough to check for the main
carbapenemases present in Acinetobacter. Of all the
carbapenemases described in A. baumannii, oxacillinases
are by far the most frequently found among the most prevalent
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TABLE 1 | Eazyplex SuperBug Complete A kit was used to detect









A. baumannii 1 OXA-23 103 14:00
102 16:15
A. baumannii 2 OXA-23 103 11:45
102 –
A. baumannii 3 OXA-23 103 28:00
102 21:15
A. baumannii 4 OXA-23 103 13:00
102 –
A. baumannii 5 OXA-23 103 11:15
102 14:15
A. baumannii 6 OXA-40 103 12:50
102 13:15
A. baumannii 7 OXA-40 103 13:30
102 –
A. baumannii 8 OXA-40 103 11:30
102 17:00
A. baumannii 9 OXA-40 103 9:45
102 –
A. baumannii 10 OXA-40 103 9:30
102 10:30
A. baumannii 11 OXA-58 103 16:10
102 18:30
A. baumannii 12 OXA-58 103 16:15
102 –







A. baumannii 14 OXA-58 103 9:30
102 10:00
A. baumannii 15 OXA-58 103 12:15
102 12:45






A. baumannii 16 NDM 103 –
102 –
A. baumannii 17 NDM 103 13:45
102 –
A. junii 1 IMP-1* IMP 103 –
102 –
A. baumannii 18 IMP-2* IMP 103 –
102 –
Eazyplex R© SuperBug Complete A detection time per concentration tested for
each of the Acinetobacter spp. strains tested. “–” indicates no detection of
the carbapenemase-producing gene in the concentration tested. *IMP-producing
strains were included in the study to cover the range of carbapenemases found in
Acinetobacter although not being detected in the kit.
clones, being the international clone 2 OXA-23 producing
A. baumannii worldwide spread.
Detection of carbapenemase-producing genes in the tested
strains using Eazyplex SuperBug Complete A assay is shown
in Table 1, and the results agree with conventional PCR
results. Detection time values vary per strain and gene. Only
15 concentrations tested out of 44 did not provide detection
of the carbapenemase-producing gene, all being at the lowest
concentration tested at 102 CFU/ml; therefore, with the limit
of sensitivity being 103 CFU/ml, we consider that this kit has
enough sensitivity for the detection of carbapenemase-producing
Acinetobacter in clinical BAL samples, taking into consideration
that the cut-off for BAL is 104 CFU/ml.
With a maximum hands-on time of 15 min per sample and
30 min run time (approximately 45 min total), this assay proves
to be a great advantage compared to routine methods in the
clinical microbiology laboratory that need 16–24 h for results
to be obtained. Naturally, further antimicrobial susceptibility
testing should be considered in all samples. The only rapid test
(4 h) that allows the detection of the most frequent pathogens
causing HAP is the Unyvero Hospitalized Pneumonia (HPN;
Curetis GmbH, Germany). This multiplex panel also includes
some resistant markers (18 in total); among them, it can detect
the genes encoding VIM, IMP, NDM, KPC, OXA-23, OXA-24,
OXA-48, and OXA-58. However, as far as we know, it has not
been validated for detection of carbapenemases in A. baumannii.
We visualize the following workflow for diagnosis of hospital-
acquired pneumonia (HAP): when the sample arrives to the
clinical microbiology laboratory, rapid identification of the
bacteria causing HAP is performed also using an in-house LAMP
reaction approach (Vergara et al., 2020a); if A. baumannii is
identified as the pathogen causing the infection, the method to
detect specific carbapenemases in Acinetobacter described in this
study is performed. However, if Enterobacterales is detected, the
same approach can be applied (Vergara et al., 2020b).
Using Eazyplex R© SuperBug Complete A assay will allow to
guide and optimize antibiotic therapies earlier than with usual
techniques used in the laboratory, which likely means a decrease
in mortality. This assay represents the kind of advantages that
investing in molecular diagnostics brings to the clinical practice:
allows the identification of specific resistance mechanisms in
approximately 45 min and if sample identification using LAMP
was included as a first step (1 h), both pathogen and resistance
mechanism could be identified in less than 2 h.
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